Lege Artis Medicinae

[A farewell to Róbert Frenkl]

KAPÓCS Gábor

MARCH 20, 2010

Lege Artis Medicinae - 2010;20(03-04)

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Haitian Fates]

NAGY Zsuzsa

Lege Artis Medicinae

[Changing of the guard - The end of an era]

KAPÓCS Gábor

Lege Artis Medicinae

[HuMánia – Voluntary Peer Training for Future Physicians]

HORVÁTH Dóra Anita, DOMBI Anna Zsófia, FÉSŰS Szilvia, ROSTA Eszter Andrea, SÁNDOR Zsuzsanna, HEGEDŰS Katalin

Lege Artis Medicinae

[From Degas to Picasso – French Masterpieces from Pushkin Museum, Moscow]

NEMESI Zsuzsanna

Lege Artis Medicinae

[The Ferenczi Cult, the Therapeutic Technique and the “Dodo Hypothesis”]

BÁNFALVI Attila

All articles in the issue

Related contents

Lege Artis Medicinae

[Farewell to a Special Physician who Loved Literature – Remembering István Kiss MD]

MOLNÁR-TAGA Márta, VASAS Lívia

Hungarian Radiology

[A farewell to professor Ernő MakóA farewell to Ernő]

AZ MRT vezetősége, MESTER Ádám

Lege Artis Medicinae

[Saying Farewell]

KISS Erika

Clinical Neuroscience

[Péter Halász, Róbert Bódizs: Dynamic structure of NREM sleep]

BORBÉLY Alexander

[We spend four fifths of our sleep time in nonREM (NREM) sleep. The rather strange designation of this sleep state was a consequence of the fascination by rapid-eye-movement sleep (REM sleep) after its discovery in the middle of the last century.]

Lege Artis Medicinae

[Farewell to rosiglitazone: where to go?]

TAMÁS GYULA, KERÉNYI ZSUZSA

[The European Medicines Agency concluded that the marketing authorisation for all rosiglitazonecontaining medicines (Avandia, Avandamet, Avaglim) should be suspended across the European Union. The National Health Insurance Fund Administration in Hungary in a circular letter called the attention of GP’s to the necessity in getting the medical proposal (of an internist, endocrinologist or diabetologist) for substituting rosiglitazone to arrange a smooth modification of their treatment regimen. The review taking into account updated recommendations of the ADA-EASD and the Hungarian Diabetes Association summarises the potential drugs. The first line therapy of choice has to be starting with insulin. Pioglitazone might also be administered, with all known side effects of the glitazone family, e.g. congestive heart failure and bone fractures. Further alternatives are choosing the newer drugs of the incretin principle: the incretin mimetics (exenatid, liraglutid) and the incretin enhancers (sitagliptin, vildagliptin, saxagliptin). Beside their favourable profile of effect they do not have longterm follow up outcome studies and evidences for cardiovascular safety.]